Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after...

Area of Science:

• Oncology
• Immunotherapy
• Cancer Research

Background:

• Non-small cell lung cancer (NSCLC) presents a significant therapeutic challenge with a poor prognosis.
• Membrane-bound Hsp70 (mHsp70), expressed on high-risk NSCLC tumors, is a potential target for immunotherapy.
• Natural killer (NK) cells offer a promising avenue for targeting mHsp70-positive NSCLC.

Purpose of the Study:

• To evaluate the tolerability and efficacy of ex vivo-activated NK cells in NSCLC patients following radiochemotherapy (RCT).
• To explore NK cell therapy as a potential treatment for advanced NSCLC.
• To investigate the impact of NK cell therapy on progression-free survival (PFS) and quality of life (QoL).

Main Methods:

• A randomized phase II clinical trial comparing autologous NK cells activated ex vivo with TKD/IL2 (INT arm) versus RCT alone (CTRL arm).
• Patients with unresectable, mHsp70-positive NSCLC (stage IIIa/b) received 4 cycles of therapy post-RCT.
• Primary endpoint was PFS; secondary endpoints included QoL (QLQ-LC13), toxicity, and immunobiological responses.

Main Results:

• NK cell therapy post-RCT was well-tolerated with no significant differences in QoL between arms.
• Estimated 1-year PFS probability was 67% in the INT arm versus 33% in the CTRL arm.
• Clinical responses in the INT group correlated with an increased prevalence of activated NK cells in peripheral blood.

Conclusions:

• Ex vivo TKD/IL2-activated autologous NK cells are well-tolerated in advanced NSCLC patients after RCT.
• This NK cell therapy demonstrates positive clinical responses, indicating potential efficacy.
• NK cell immunotherapy represents a promising strategy for NSCLC treatment following standard care.